Salvinorin A: Difference between revisions

Line 13:

==Pharmacology==

Salvinorin A is a potent [[κ-opioid]] receptor [[agonist]]. It does not have any effect on the 5-HT<sub>2A</sub> receptor, the receptor targeted by most [[psychedelic]] drugs, nor does it function as an NMDA receptor antagonist as most dissociatives do. Its unique structure lacks features commonly associated with opioid ligand binding, namely it doesn't contain a quaternary carbon atom linked to a tertiary amine group by two other carbon atoms. Unlike traditional opioid agonists, salvinorin A targets the [[κ-opioid]] receptor rather than the [[μ-opioid]] receptor. Salvinorin A is currently being researched in relation to its properties as an anti-addiction drug, and several analogs with improved pharmacokinetic profiles have been shown to have anti-addictive effects as well.<ref>http://www.ncbi.nlm.nih.gov/pubmed/24484985</ref>

Salvinorin A is a potent [[Opioid#Kappa_.28.CE.BA.29|κ-opioid]] receptor [[agonist]]. It does not have any effect on the 5-HT<sub>2A</sub> receptor, the receptor targeted by most [[psychedelic]] drugs, nor does it function as an NMDA receptor antagonist as most dissociatives do. Its unique structure lacks features commonly associated with opioid ligand binding, namely it doesn't contain a quaternary carbon atom linked to a tertiary amine group by two other carbon atoms. Unlike traditional opioid agonists, salvinorin A targets the [[Opioid#Kappa_.28.CE.BA.29|κ-opioid]] receptor rather than the [[Opioid#Mu_.28.CE.BC.29|μ-opioid]] receptor. Salvinorin A is currently being researched in relation to its properties as an anti-addiction drug, and several analogs with improved pharmacokinetic profiles have been shown to have anti-addictive effects as well.<ref>http://www.ncbi.nlm.nih.gov/pubmed/24484985</ref>

However, the role of these interactions and how they result in a [[hallucinogen]]ic experience continues to remain elusive.

@@ Line 13: / Line 13: @@
 ==Pharmacology==
-Salvinorin A is a potent [[κ-opioid]] receptor [[agonist]]. It does not have any effect on the 5-HT<sub>2A</sub> receptor, the receptor targeted by most [[psychedelic]] drugs, nor does it function as an NMDA receptor antagonist as most dissociatives do. Its unique structure lacks features commonly associated with opioid ligand binding, namely it doesn't contain a quaternary carbon atom linked to a tertiary amine group by two other carbon atoms. Unlike traditional opioid agonists, salvinorin A targets the [[κ-opioid]] receptor rather than the [[μ-opioid]] receptor. Salvinorin A is currently being researched in relation to its properties as an anti-addiction drug, and several analogs with improved pharmacokinetic profiles have been shown to have anti-addictive effects as well.<ref>http://www.ncbi.nlm.nih.gov/pubmed/24484985</ref>
+Salvinorin A is a potent [[Opioid#Kappa_.28.CE.BA.29|κ-opioid]] receptor [[agonist]]. It does not have any effect on the 5-HT<sub>2A</sub> receptor, the receptor targeted by most [[psychedelic]] drugs, nor does it function as an NMDA receptor antagonist as most dissociatives do. Its unique structure lacks features commonly associated with opioid ligand binding, namely it doesn't contain a quaternary carbon atom linked to a tertiary amine group by two other carbon atoms. Unlike traditional opioid agonists, salvinorin A targets the [[Opioid#Kappa_.28.CE.BA.29|κ-opioid]] receptor rather than the [[Opioid#Mu_.28.CE.BC.29|μ-opioid]] receptor. Salvinorin A is currently being researched in relation to its properties as an anti-addiction drug, and several analogs with improved pharmacokinetic profiles have been shown to have anti-addictive effects as well.<ref>http://www.ncbi.nlm.nih.gov/pubmed/24484985</ref>
 However, the role of these interactions and how they result in a [[hallucinogen]]ic experience continues to remain elusive.